查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136909

2022-2029 年全球代謝組學市場

Global Metabolomics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

代謝組學市場的增長受到研發支出增加、靶向治療的廣泛採用、技術進步、醫療和研發支出增加以及臨床應用技術採用增加的推動。

研發費用增加有望推動市場增長

預計在預測期內，私營和政府組織對研發的資金不斷增加將提振市場。例如，加拿大創新基金會的重大科學計劃基金向代謝組學創新中心 (TMIC) 提供了 8,879,183 美元，向 Glyconet Integration Services (GIS) 提供了 1,064,968 美元，使這些中心成為糖組學和代謝組學等領域的先驅。我們支持繼續的綜合研究。

此外，市場參與者正在採用收購、合作和產品發布等市場策略。例如，2020 年，丹納赫公司收購了 GE Healthcare 的生命科學業務。同樣在 2020 年，安捷倫和賽默飛世爾擴展了他們的協議，以增強賽默飛世爾分析系統與安捷倫 OpenLAb 色譜數據系統之間的兼容性。

2020 年，沃特世公司宣佈在劍橋肯德爾廣場中心開設其研究機構 Immerse Cambridge。憑藉區域性戰略合作場所 Immerse Cambridge，沃特世將與學術界和研究機構合作，加速下一個科學發現。 2020年，我們收購了日立高新技術的剩餘股份，使其成為子公司。該子公司將負責測量和分析設備的製造以及芯片製造設備和工業材料和系統的開發。

數據複雜性阻礙市場增長

然而，由於小分子代謝物的化學多樣性，不可能用單一的分析方法分析整個代謝組。因此，對於物理存儲、準確和徹底的分析和可視化的合適軟件/數據庫的需求越來越大。此外，獲得的數據也變得越來越複雜。因此，生命科學研究過程中產生的數據的複雜性以及與其處理相關的挑戰預計將限制代謝組學市場的發展。

COVID-19 影響分析

COVID-19 的出現對全球代謝組學市場產生了相當大的影響。根據 2022 年 1 月發表在《科學報告》上的一篇文章，雖然一些代謝組學研究使用了核磁共振 (NMR)，但基於質譜 (MS) 的代謝組學在 COVID-19 疾病中具有前景。它是識別候選者的首選方法診斷生物標誌物。代謝組學已被用於解決與 COVID-19 疾病相關的各種主題。例如，代謝組學顯示恢復期非重症 COVID-19 患者的性別特異性代謝變化，表明血漿代謝的主要變化是男性的脂肪酸以及男性和女性的甘油磷酸膽鹼和碳水化合物。如代謝組學所示，肺功能受損的 COVID-19 倖存者的血漿代謝物譜可能與健康供體和肺功能正常的患者區分開來。

此外，在大流行期間，主要參與者都在從事研究活動。例如，2020年12月，布魯克公司開發的FluoroType SARS-CoV-2/Flu/RSV Winter 4-plex PCR panel對SARS-CoV-2病毒、流感病毒A和B、呼吸道同時檢測網狀病毒（RSV）具有高敏感性。

2020 年 7 月，布魯克公司宣布“FluoroType SARS-CoV-2 plus 下一代 6-plex PCR 檢測”上市銷售。

全球代謝組學市場報告由大約 60 多個市場數據表、55 多個數字和 200 多個（大約）頁組成。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 技術進步
      • 對代謝組學治療的需求不斷擴大
    • 約束因素
      • 代謝組學設備成本高
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品/服務分類

  • 分離技術
    • 色譜法
    • 液相色譜
    • 氣相色譜
    • 毛細管電泳
  • 檢測技術
    • 核磁共振波譜
    • 質譜
    • 其他
  • 生物信息學工具和服務

第 8 章. 按應用程序

  • 營養基因組學
  • 生物標誌物和藥物發現
  • 毒理學測試
  • 個性化醫療
  • 其他

第 9 章適應症

  • 癌症
  • 神經系統疾病
  • 先天性代謝紊亂
  • 心血管疾病
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 12 章公司簡介

  • Thermo Fisher Scientific Inc.
    • 公司簡介
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • Bio-Rad Laboratories
  • Agilent Technologies Inc.
  • Danaher Corporation
  • Waters Corporation
  • Bruker Corporation
  • Human Metabolome Technologies, Inc.
  • Metabolon Inc.
  • LECO Corporation
  • Shimadzu Corporation

第 13 章全球代謝組學市場-DataM

簡介目錄
Product Code: DMMD448

Market Overview

Metabolomics Market was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 11.2% during the forecast period (2022-2029).

In metabolomics, biological metabolites are identified and quantified using sophisticated analytical techniques, and information is extracted and interpreted using statistical and multivariate approaches. LC-MS/MS, GC-MS, and/or NMR are some of the complimentary analytical techniques used in metabolomics to identify and quantify as many known and unidentified metabolites as possible.

Market Dynamics

The metabolomics market growth is driven by the rising funding in research and development, rising adoption of targeted therapies, technological advamcement, increasing healthcare and R&D expenditure, rise in adoption of technology for clinical applications.

The rising funding for reserch and development is expected to drive the market growth

The rising funding for research and development from private and government organizations is expected to boost the market over the forecast period. For instance, the Canadian Foundation for Innovation's Major Science Initiatives Fund has provided $8,879,183 to The Metabolomics Innovation Centre (TMIC) and $10,684,968 to GlycoNet Integrated Services (GIS), helping these centers to continue their pioneering research, including glycomics and metabolomics.

In addition, the market players are adopting market strategies, including acquisition, collaboration and product launches. For instance, in 2020, Danaher Corporation acquired GE Healthcare's Life Sciences business. Also, In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fisher's analytical systems with Agilent's OpenLAb Chromatography Data System.

In 2020, Waters Corporation announced the opening of Immerse Cambridge, a research facility in the center of Kendall Square in Cambridge. The community's strategic, collaborative venue, Immerse Cambridge, will allow Waters to work with academia and research to accelerate the next round of scientific discoveries. Also, in 2020, Hitachi acquired the remaining shares of Hitachi High-Technologies billion and made it is subsidiary. This subsidiary will be responsible for manufacturing measuring and analytical equipment, along with developing chipmaking equipment and industrial materials and systems.

The complexity of the data will hamper the growth of the market

However, no one analytical method can be used to analyze the full metabolome due to the chemical diversity of small molecule metabolites. Therefore, there is an increased demand for physical storage, accurate and thorough analysis, and appropriate software/databases for visualization. The resulting data is also more complicated. Therefore, it is anticipated that the complexity of the data produced during life science research and the challenges associated with handling it will restrain the development of the metabolomics market.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global metabolomics market. As per the article published in Scientific Reports in January 2022, While some metabolomics studies have used nuclear magnetic resonance (NMR), mass spectrometry (MS)-based metabolomics has been the method of choice for identifying prospective diagnostic biomarker candidates in COVID-19 disease. Metabolomics has been used to address various topics related to COVID-19 disease. For example, metabolomics has shown sex-specific metabolic shifts in non-severe COVID-19 patients during recovery, demonstrating that the major plasma metabolic changes were fatty acids in men and glycerophosphocholines and carbohydrates in men and women. As demonstrated by metabolomics, plasma metabolite profiles of COVID-19 survivors with impaired pulmonary function may be distinguished from those of healthy donors or those with normal pulmonary function.

In addition, the key players are engaged in research activities during the pandemic. For instance, in December 2020, The FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, developed by Bruker Corporation, allows for the sensitive and simultaneous detection of the SARS-CoV-2 virus, influenza viruses A and B, as well as the respiratory syncytial virus (RSV)

Also, in July 2020, The FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay was introduced by Bruker Corporation to precisely identify the SARS-CoV-2 virus, which is responsible for the respiratory and systemic illness COVID-19.

Segment Analysis

The separation technique segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The separation technique segment is expected to boost the market throughout the forecast. As per the article published in Novel Approaches in Drug Designing & Development in August 2021, the analytical technique of liquid chromatography is used to isolate the target analyte from the mixture. To effectively separate molecules of interest, liquid chromatography uses a liquid as the mobile phase and a solid as the stationary phase. Mass spectroscopy is performed to determine the molecular mass of the sample of interest. By measuring the sample ion's mass to charge ratio, the molecule's mass is ascertained. Due to its selectivity, low sample volume requirements, sensitivity, and speed, the combination of liquid chromatography and mass spectrometry (LC-MS) is a potent instrument with several applications. LC is now compatible with MS due to creative and fruitful research over the past few years on constructing a potential interface link between the two. In the preclinical development stage, LC-MS detects impurities, degradants, and metabolites. In addition, the use of LC-MS/MS for protein quantification has attracted much attention. It is employed in the detection of biomarkers.

Geographical Analysis

North America region holds the largest market share of the global Metabolomics market

North America dominates the metabolomics market and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to government initiatives, growth and development research activities in metabolomics, and an increase in the adoption of metabolomics in precision medicine.

The primary aim of the Metabolomics Association of North America (MANA) is to advance the field of metabolomics, particularly in North America; to give North American researchers in metabolomics sciences and related fields the chance to network; to facilitate connections between academia and industry; to provide venues for the presentation of research findings and for workshops, and to encourage the publication of metabolomics research.

In addition, in April 2020, Gilead Sciences, Inc., and Second Genome, entered into a four-year strategic collaboration to find potential new targets and drug candidates for the treatment of inflammatory bowel disease as well as to identify biomarkers linked to clinical response in up to five of Gilead's pipeline compounds for the treatment of fibrosis, inflammation, and other diseases (IBD).

Competitive Landscape

The metabolomics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Agilent Technologies Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, Human Metabolome Technologies, Inc., Metabolon Inc., LECO Corporation, and Shimadzu Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, contributing to the growth of the global metabolomics market.

For instance,

  • In June 2021, Bruker Corporation launched the FluoroType SARS-CoV-2 varied Q assay, a quantitative Liquid Array mid-plexPCR panel. This novel assay panel also detects several important mutations, enabling laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The assay achieved a sensitivity of 98% and a specificity of 100% during its clinical performance evaluation study.
  • In June 2021, at Bruker's virtual 4D-Proteomics eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation launched the two new Tim stop instruments. In addition, they advance and enable new applications and methods in unbiased proteomics/PTM characterization and unbiased, deep multi-omic biomarker discovery, for example, in cancer liquid biopsy research.

Thermo Fisher Scientific Inc

Overview:

Thermo Fisher Scientific Inc. is an American company founded in 1956 and headquartered in the United States. It provides solutions including chromatographic separations such as GC, LC and IC. It produces novel, stringent and reproducible results for high-impact discoveries.

Treatment type Portfolio:

Orbitrap Exploris GC 240: Thermo Scientific Orbitrap Exploris GC 240 mass spectrometer facilitates the most difficult analytical challenges. It delivers uncompromising qualitative and quantitative information and provides the need for research laboratories for compound identification and quantitation, including discovery profiling, metabolomics, industry research and applied quantification analyses, to gain unparalleled access to information-rich data with ease.

The global metabolomics market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
      • 4.1.1.2. Rising demand for metabolomics therapy
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of metabolomics instruments
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product and Services

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 7.1.2. Market Attractiveness Index, By Product and Services
  • 7.2. Separation Techniques*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Chromatography
    • 7.2.4. Liquid Chromatography
    • 7.2.5. Gas Chromatography
    • 7.2.6. Capillary Electrophoresis
  • 7.3. Detection Techniques
    • 7.3.1. Nuclear Magnetic Resonance Spectroscopy
    • 7.3.2. Mass Spectrometry
    • 7.3.3. Others
  • 7.4. Bioinformatics Tools and Services

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Nutrigenomics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biomarker & Drug Discovery
  • 8.4. Toxicology Testing
  • 8.5. Personalized Medicine
  • 8.6. Others

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication
  • 9.2. Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Neurological Disorders
  • 9.4. Inborn Errors of Metabolism
  • 9.5. Cardiovascular Disorders
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Thermo Fisher Scientific Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Rad Laboratories
  • 12.3. Agilent Technologies Inc.
  • 12.4. Danaher Corporation
  • 12.5. Waters Corporation
  • 12.6. Bruker Corporation
  • 12.7. Human Metabolome Technologies, Inc.
  • 12.8. Metabolon Inc.
  • 12.9. LECO Corporation
  • 12.10. Shimadzu Corporation

LIST NOT EXHAUSTIVE

13. Global Metabolomics market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us